RE-BVS – Piemonte Repository

Sfoglia per AUTORE
TAMBURINI E
Collezione AO Cuneo

Items : 6

TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. in Cancers / Cancers (Basel). 2021 Jun 7;13(11):2839. doi: 10.3390/cancers13112839.

2021
AO Ordine Mauriziano
AO Cuneo

Zaniboni A; Tamburini E; Tamberi S; Strippoli A; Spallanzani A; Smiroldo V; Silvestris N; Ratti M; Pucci F; Ongaro E; Murialdo R; Lonardi S; Iachetta F; Granetto C; Fornaro L; Frassineti GL; Di Maio M; De Vita F; De Manzoni G; Cardellino GG; Berardi R; Aprile G; Antonuzzo L; Aglietta M; Prisciandaro M; Di Bartolomeo M; Palermo F; Raimondi A; Cremolini C; et alii...

Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2020 Nov;139:81-89. doi: 10.1016/j.ejca.2020.08.009. Epub 2020 Sep 23.

2020
AO Cuneo

Aprile G; Falcone A; Grande R; Boccaccino A; Fea E; Tamburini E; Bordonaro R; Marmorino F; Buonadonna A; Pietrantonio F; Zaniboni A; Antoniotti C; Caponnetto S; Tomasello G; Cupini S; Santini D; Bergamo F; Lonardi S; Zucchelli G; Moretto R; Rossini D; Cremolini C;

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. in The Lancet. Oncology / Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9.

2020
AOU Città della Salute di Torino
AO Cuneo

Fenocchio E; Mammoliti S; Cupini S; Roselli M; Mambrini A; Ritorto G; Clavarezza M; Carlomagno C; Di Donato S; Ronzoni M; Masi G; Tomasello G; Antonuzzo L; Corallo S; Cordio S; Moretto R; Buonadonna A; Granetto C; Murgioni S; Zaniboni A; Aprile G; Grande R; Marmorino F; Passardi A; Santini D; Tamburini E; Latiano TP; Bordonaro R; Pietrantonio F; et alii...

Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2019 Dec 1;30(12):1969-1977. doi: 10.1093/annonc/mdz403.

2019
AO Cuneo

Marmorino F; Rossini D; Lonardi S; Moretto R; Zucchelli G; Aprile G; Dell'Aquila E; Ratti M; Bergamo F; Masi G; Urbano F; Ronzoni M; Libertini M; Borelli B; Randon G; Buonadonna A; Allegrini G; Pella N; Ricci V; Boccaccino A; Latiano TP; Cordio S; Passardi A; Tamburini E; Boni L; Falcone A; Cremolini C;

Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC in Journal of Clinical Oncology

2019
AO Cuneo

Cremolini C; Antoniotti C; Lonardi S; Rossini D; Pietrantonio F; Cordio SS; Bergamo F; Marmorino F; Maiello E; Passardi A; Masi G; Tamburini E; Santini D; Grande R; Zaniboni A; Granetto C; Murgioni S; Aprile G; Boni L; Falcone A;

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. in BMC cancer / BMC Cancer. 2017 Jun 9;17(1):408. doi: 10.1186/s12885-017-3360-z.

2017
AO Cuneo

Santini D; Allegrini G; Di Donato S; Passardi A; Tomasello G; Valsuani C; Pietrantonio F; Ronzoni M; Ricci V; Tamburini E; Aprile G; Lonardi S; Zagonel V; Boni L; Schirripa M; Salvatore L; Antoniotti C; Masi G; Loupakis F; Marmorino F; Cremolini C; Falcone A;